132 related articles for article (PubMed ID: 2306795)
1. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Schwartsmann G; Dodion P; Vermorken JB; ten Bokkel Huinink WW; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh WJ; van Hennik MB
Cancer Chemother Pharmacol; 1990; 25(5):345-51. PubMed ID: 2306795
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.
de Forni M; Chabot GG; Armand JP; Fontana X; Recondo G; Domenge C; Carde P; Barbu M; Gouyette A
Eur J Cancer; 1993; 29A(7):983-8. PubMed ID: 8499153
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
[TBL] [Abstract][Full Text] [Related]
5. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
Burris HA; Raymond E; Awada A; Kuhn JG; O'Rourke TJ; Brentzel J; Lynch W; King SY; Brown TD; Von Hoff DD
Invest New Drugs; 1998; 16(1):19-27. PubMed ID: 9740540
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
Bork E; Vest S; Hansen HH
Eur J Cancer Clin Oncol; 1989 Oct; 25(10):1403-11. PubMed ID: 2591433
[TBL] [Abstract][Full Text] [Related]
8. Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Schwartsmann G; Bork E; Vermorken JB; Nieboer C; Dodion P; ten Bokkel Huinink WW; Seldenrijk CA; Armand JP; Pinedo HM
Cancer; 1989 Jan; 63(2):243-8. PubMed ID: 2521297
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
Schwartsmann G; van der Vijgh WJ; van Hennik MB; Klein I; Vermorken JB; Dodion P; ten Bokkel Huinink WW; Joggi G; Gall H; Crespeigne N
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1675-81. PubMed ID: 2632251
[TBL] [Abstract][Full Text] [Related]
11. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Peters GJ; Kraal I; Pinedo HM
Br J Cancer; 1992 Feb; 65(2):229-33. PubMed ID: 1739622
[TBL] [Abstract][Full Text] [Related]
15. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
16. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Terret C; Zanetta S; Roché H; Schellens JH; Faber MN; Wanders J; Ravic M; Droz JP;
Eur J Cancer; 2003 May; 39(8):1097-104. PubMed ID: 12736109
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer.
Maroun J; Ruckdeschel J; Natale R; Morgan R; Dallaire B; Sisk R; Gyves J
Cancer Chemother Pharmacol; 1993; 32(1):64-6. PubMed ID: 8384937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
